XBiotech (United States)

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

David S. Hong, David Hui, Éduardo Bruera et al. · The Lancet Oncology · 2014 · 192 citations

Cancer Immunosurveillance, Medicine, Immunology +7

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

Tamas Hickish, Thierry André, Lucjan Wyrwicz et al. · The Lancet Oncology · 2017 · 153 citations

Novel Antibody Treatment, Medicine, Immunology +7

Enhanced Keratinocyte Proliferation and Migration in Co-culture with Fibroblasts

Zhenxiang Wang, Ying Wang, Farhang Farhangfar et al. · PLoS ONE · 2012 · 124 citations · Full text

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study

Theodora Kanni, M. Argyropoulou, Themistoklis Spyridopoulos et al. · Journal of Investigative Dermatology · 2017 · 108 citations · Full text

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain

Alice B. Gottlieb, Nicola E. Natsis, Francisco A. Kerdel et al. · Journal of Investigative Dermatology · 2020 · 85 citations

Inflammatory Lesions, Pathology, Clinical Dermatology +3